Find clinical trials

This study aims to determine whether the small airways, a site of physiological dysfunction in asthma, can be targeted with bronchodilator therapy, by using a small particle size aerosol that reaches the lung periphery. Current clinical management of patients with asthma includes an array of inhaled therapies. However, there is no consensus relating to the efficacy of different particle sizes for inhalation, despite particle size being the main determinant of where the drug deposits in the airway. Participants with asthma will be invited to participate in two study visits. Both study visits will involve physiological assessments (lung function tests) and ventilation scans completed at baseline and post-bronchodilator. At one visit the standard medication salbutamol will be administered via a conventional vibrating mesh nebuliser (Aerogen solo), at the other visit the salbutamol will be administered via the Aerogen PDAP which will create a fine particle aerosol. The aim is 2 recruit and test 30 participants and compare their response to small and large particle bronchodilator.

This prospective, intra-subject controlled trial will evaluate the effect of Intense Pulsed Light (IPL) therapy on vascularity and scar outcomes in 20 adults with split-thickness skin graft donor sites at increased risk of hypertrophic scarring. Each participant will have two comparable donor-site areas, with one receiving IPL plus standard scar management and the other receiving standard scar management alone as an intra-subject control. IPL treatment will commence 12 weeks after complete epithelialisation, with three treatment sessions at eight-week intervals. Scar vascularity will be objectively assessed using Antera 3D imaging, with secondary outcomes including scar quality using POSAS 3.0 and health-related quality of life using the EQ-5D. Participants will be followed for 12 months following the final treatment.

This registry will contribute data to the Gore Together Aortic Registry (Together Registry). The Together Registry is an observational, prospective multi-regional registry collecting real-world data for commercially available aortic endovascular products under aligned, but independent product registry protocols. Data relevant to all aortic endovascular procedures (e.g., subject demographics, medical history, basic treatment outcomes, core outcomes, etc.) will be consistently collected across all Gore aortic endovascular product protocols included in the Together Registry. These core data will be collected using consistent Case Report Forms (CRFs) and analyzed using consistent measures and definitions. The overall registry design permits product-specific protocols to capture and report novel data that does not represent a generalizable outcome for all involved Gore products.

This research study is looking at whether the oral supplement TRU NIAGEN®, a form of Vitamin B, can increase the levels of the molecule NAD+ in the blood and heart muscle. NAD+ is essential for energy production in the human body. Research has shown decreased NAD+ levels in the heart muscle of patients with a condition of heart failure known as heart failure with preserved ejection fraction (HFpEF) or stiff heart failure. TRU NIAGEN® has been shown to increase the level of NAD+ in the blood, however whether it can increase NAD+ in the heart muscle is unknown. Replenishing NAD+ in the heart could be beneficial to HFpEF patients and/ or patients whose hearts don’t relax properly. The aim of the study is to see whether taking the oral supplement TRU NIAGEN® for three months can improve your heart function, exercise tolerance, glucose tolerance, and blood pressure.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia globally contributing significantly to cardiovascular morbidity and mortality. Obesity is a well-established modifiable risk factor for AF and is present in 2/3 of patients with AF. The SEMOAF study aims to randomise 220 patients with AF and overweight/obesity to semaglutide 2.4 mg weekly vs placebo to determine the impact of weight loss on AF recurrence and burden.

We are inviting patients who undergo thyroid nodular ablation to allow us to include their coded treatment and outcome information in the study so we can better understand the effectiveness and safety of the procedure over time. Thyroid nodular ablation is a relatively new treatment in Australia, first introduced in April 2021, and there is still limited information about its long-term outcomes. To help strengthen this knowledge, we are conducting the thyroid ablation study (the TArgeT study).

Significant blood dilution occurs during cardiac surgery involving cardiopulmonary bypass. One way to minimise this is a technique called retrograde autologous priming (RAP) whereby the patient’s own blood is used to prime the bypass circuit instead of a clear fluid solution. This study aims to assess the feasibility of a full-scale trial to determine if the routine use of RAP decreases the amount of blood transfused up to 72 hours post-surgery.

Many people with epilepsy still have seizures despite medication, and current treatments like surgery or deep brain stimulation don't work for everyone. This study will use temporary electrodes placed in deeper parts of the brain during routine epilepsy evaluations to test different stimulation approaches, helping doctors find the best personalised treatment for each person.